Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...

The program is examining the effectiveness of a protocol meant to ensure safety for pilots and air traffic controllers on ...

Pharmaceutical giant Pfizer is set to reduce its workforce in Ireland as it faces ongoing challenges in the wake of the COVID ...

Mercury vs Novo Business Checking (2024): Which Is Best? Your email has been sent Compare Mercury and Novo Business Checking accounts to determine the best fit for your business. Explore pricing ...

SAO PAULO (Reuters) - Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for pumping out a quarter of its insulin production ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.